Breaking News Instant updates and real-time market news.

MNOV

MediciNova

$8.29

0.01 (0.12%)

19:02
04/01/19
04/01
19:02
04/01/19
19:02

MediciNova 'excited' with results of SPRINT-MS Phase 2b trial subgroup analysis

MediciNova announced results from its subgroup analysis of the SPRINT-MS Phase 2b trial of MN-166 in progressive multiple sclerosis. This subgroup analysis was conducted based on recent feedback MediciNova received from the FDA that relapsing secondary progressive MS is different from non-relapsing secondary progressive MS as non-relapsing secondary progressive MS is the only type of secondary progressive MS without available therapy. The purpose of the subgroup analysis was to provide information about which types of progressive MS subjects responded best to MN-166 treatment in terms of the clinically significant endpoint of the risk of confirmed disability progression compared to placebo, as measured by EDSS. Confirmed disability progression was a secondary endpoint in this Phase 2b trial but would be considered a primary endpoint in Phase 3. Unlike the magnetic resonance imaging endpoint of whole brain atrophy, which is not a clinical endpoint, confirmed disability progression is the most important clinical endpoint and is the basis for FDA approval of progressive MS drugs. The trends for reduction in the risk of confirmed disability progression were highest for the subgroup of subjects with Secondary Progressive MS without Relapse, in which MN-166 demonstrated a 46% risk reduction compared to placebo as indicated by the hazard ratio of 0.538. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc. commented, "We are excited with the results of our subgroup analysis. Although two drugs have recently received FDA approval for relapsing secondary progressive MS, there remains a very large unmet medical need for secondary progressive MS patients without relapses as there is still no drug approved for long-term treatment of these patients. Based on our extensive analysis of the SPRINT-MS data including this subgroup analysis, we are finalizing the optimal trial design for what we believe will be a very successful Phase 3 program and we plan to submit this trial design to the FDA shortly. With a convenient oral administration, a very favorable safety and tolerability profile, and the potential for better efficacy than other drugs for progressive MS, we believe ibudilast could become the best-in-disease drug."

  • 23

    Apr

  • 24

    Apr

MNOV MediciNova
$8.29

0.01 (0.12%)

03/25/19
RILY
03/25/19
INITIATION
Target $22
RILY
Buy
MediciNova asumed with a Buy at B. Riley FBR
B. Riley FBR analyst Chad Mabry assumed coverage of MediciNova with a Buy rating and $22 price target.

TODAY'S FREE FLY STORIES

DGX

Quest Diagnostics

$102.21

-0.465 (-0.45%)

06:50
10/22/19
10/22
06:50
10/22/19
06:50
Earnings
Quest Diagnostics reports Q3 adj. EPS $1.76, consensus $1.71 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 28

    Oct

  • 04

    Nov

  • 07

    Dec

HAS

Hasbro

$120.11

-1.78 (-1.46%)

06:49
10/22/19
10/22
06:49
10/22/19
06:49
Hot Stocks
Hasbro to suspend share repurchase program »

At quarter-end, $367.8M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

MTG

MGIC Investment

$13.74

0.22 (1.63%)

06:48
10/22/19
10/22
06:48
10/22/19
06:48
Earnings
MGIC Investment reports Q3 adj. EPS 48c, consensus 42c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CIT

CIT Group

$45.65

1.36 (3.07%)

06:47
10/22/19
10/22
06:47
10/22/19
06:47
Earnings
CIT Group reports Q3 EPS $1.50, consensus $1.21 »

Reports Q3 revenue $454M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

GPK

Graphic Packaging

$14.86

0.205 (1.40%)

06:44
10/22/19
10/22
06:44
10/22/19
06:44
Earnings
Graphic Packaging reports Q3 EPS 20c, consensus 19c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

BIIB

Biogen

$223.57

3.52 (1.60%)

06:44
10/22/19
10/22
06:44
10/22/19
06:44
Hot Stocks
Biogen soars 20% on plans to pursue Alzheimer's approval after FDA talks »

Shares of Biogen are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

HLX

Helix Energy

$8.32

0.31 (3.87%)

06:43
10/22/19
10/22
06:43
10/22/19
06:43
Earnings
Helix Energy narrows FY19 revenue view to $730M-$760M from $700M-$760M »

Consensus is $749.91M.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

  • 14

    Nov

PNTG

The Pennant Group

$18.37

0.19 (1.05%)

06:43
10/22/19
10/22
06:43
10/22/19
06:43
Initiation
The Pennant Group initiated  »

The Pennant Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEBO

Peoples Bancorp

$32.28

0.57 (1.80%)

06:42
10/22/19
10/22
06:42
10/22/19
06:42
Earnings
Peoples Bancorp reports Q3 EPS 72c, consensus 70c »

Reports Q3 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

  • 04

    Dec

  • 05

    Dec

ACRS

Aclaris Therapeutics

$1.40

-0.205 (-12.77%)

06:41
10/22/19
10/22
06:41
10/22/19
06:41
Upgrade
Aclaris Therapeutics rating change  »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

FITB

Fifth Third

$28.04

0.71 (2.60%)

06:40
10/22/19
10/22
06:40
10/22/19
06:40
Hot Stocks
Fifth Third sees Q4 NII down about 1% from Q3, NIM down 4-5bps »

Sees FY19 NII up about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

ARCH

Arch Coal

$78.98

-0.1 (-0.13%)

06:39
10/22/19
10/22
06:39
10/22/19
06:39
Hot Stocks
Arch Coal backs FY19 total sales volume view 86.7- 92.1 tons »

"We are confident in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

HAS

Hasbro

$120.11

-1.78 (-1.46%)

06:39
10/22/19
10/22
06:39
10/22/19
06:39
Hot Stocks
Hasbro CEO says 'on track to deliver profitable revenue growth in 2019' »

"Hasbro remains on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

CVNA

Carvana

$77.23

3.42 (4.63%)

06:39
10/22/19
10/22
06:39
10/22/19
06:39
Recommendations
Carvana analyst commentary  »

Carvana sold 15,239…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ARCH

Arch Coal

$78.98

-0.1 (-0.13%)

06:37
10/22/19
10/22
06:37
10/22/19
06:37
Earnings
Arch Coal reports Q3 EPS $6.34, consensus $3.39 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ARES

Ares Management

$28.28

0.42 (1.51%)

, NEP

NextEra Energy Partners

$51.04

-0.54 (-1.05%)

06:37
10/22/19
10/22
06:37
10/22/19
06:37
Hot Stocks
Ares Management sells ownership in Meade Pipeline to NextEra Energy Partners »

Ares Management (ARES)…

ARES

Ares Management

$28.28

0.42 (1.51%)

NEP

NextEra Energy Partners

$51.04

-0.54 (-1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 31

    Oct

  • 04

    Dec

KOOL

Cesca Therapeutics

$5.31

-0.14 (-2.57%)

06:37
10/22/19
10/22
06:37
10/22/19
06:37
Hot Stocks
Cesca Therapeutics forms JV with Healthbanks Biotech »

Cesca Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$223.57

3.52 (1.60%)

06:36
10/22/19
10/22
06:36
10/22/19
06:36
Hot Stocks
Breaking Hot Stocks news story on Biogen »

Biogen to offer access to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

BIIB

Biogen

$223.57

3.52 (1.60%)

06:36
10/22/19
10/22
06:36
10/22/19
06:36
Hot Stocks
Breaking Hot Stocks news story on Biogen »

Biogen: Analysis of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SNV

Synovus

$36.30

1.005 (2.85%)

06:35
10/22/19
10/22
06:35
10/22/19
06:35
Earnings
Synovus reports Q3 adjusted EPS 97c, consensus 99c »

Reports Q3 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

BIIB

Biogen

$223.57

3.52 (1.60%)

, ESALY

Eisai

$0.00

(0.00%)

06:35
10/22/19
10/22
06:35
10/22/19
06:35
Hot Stocks
Biogen plans aducanumab BLA in early 2020 based on FDA talks »

Biogen (BIIB) and Eisai…

BIIB

Biogen

$223.57

3.52 (1.60%)

ESALY

Eisai

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

FBC

Flagstar Bancorp

$38.72

0.39 (1.02%)

06:34
10/22/19
10/22
06:34
10/22/19
06:34
Earnings
Flagstar Bancorp reports Q3 EPS $1.11, consensus $1.04 »

Reports Q3 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

BIIB

Biogen

$223.57

3.52 (1.60%)

, ESALY

Eisai

$0.00

(0.00%)

06:34
10/22/19
10/22
06:34
10/22/19
06:34
Hot Stocks
Breaking Hot Stocks news story on Biogen, Eisai »

Biogen plans aducanumab…

BIIB

Biogen

$223.57

3.52 (1.60%)

ESALY

Eisai

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

UBS

UBS

$11.53

0.18 (1.59%)

06:33
10/22/19
10/22
06:33
10/22/19
06:33
Periodicals
UBS to address client overcharges in Singapore, Hong Kong, Reuters reports »

UBS is working with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 12

    Nov

FITB

Fifth Third

$28.04

0.71 (2.60%)

06:33
10/22/19
10/22
06:33
10/22/19
06:33
Earnings
Fifth Third reports Q3 EPS 71c with items, consensus 73c »

Reported results included…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.